검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | TKIs |
Overview Company | Nuvalent Inc. |
Overview Modality | ADC |
Overview Target | Breast Cancer |
Overview Indication | Breast Cancer |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
MoA Mechanism | target secondary mutations and compensatory bypass pathway |
MoA Biomarker | EGFR inhibition was down-regulation of MGMT expression |
PK/PD Species | Rat, Human |
PK/PD Animal (cat.) | Human, Rat, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Rat, Human |
Toxicology Animal (cat.) | Human, Rat, In vitro |
Toxicology Major finding | Multidisciplinary Rehabilitation for Severe Respiratory Failure Due to Dasatinib-Induced Pulmonary Toxicity: A Case Report.. BACKGROUND Tyrosine kinase inhibitors (TKIs) are effective for chronic myeloid leukemia (CML), but they may cause pulmonary toxicity, including pleural effusion. In severe cases, respiratory failure requiring mechanical ventilation can occur, and weaning from the ventilator … |
Clinical Primary efficacy | ORR 8% |
Clinical ORR | 18% |
Clinical OS | 237 |
Clinical Result source | ClinicalTrials.gov NCT01657682 |
Clinical Data Tier / Score | A · 28 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | TKIs |
Overview Company | Nuvalent Inc. |
Overview Modality | ADC |
Overview Target | Breast Cancer |
Overview Indication | Breast Cancer |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
MoA Mechanism | target secondary mutations and compensatory bypass pathway |
MoA Biomarker | EGFR inhibition was down-regulation of MGMT expression |
PK/PD Species | Rat, Human |
PK/PD Animal (cat.) | Human, Rat, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Rat, Human |
Toxicology Animal (cat.) | Human, Rat, In vitro |
Toxicology Major finding | Multidisciplinary Rehabilitation for Severe Respiratory Failure Due to Dasatinib-Induced Pulmonary Toxicity: A Case Report.. BACKGROUND Tyrosine kinase inhibitors (TKIs) are effective for chronic myeloid leukemia (CML), but they may cause pulmonary toxicity, including pleural effusion. In severe cases, respiratory failure requiring mechanical ventilation can occur, and weaning from the ventilator … |
Clinical Primary efficacy | ORR 8% |
Clinical ORR | 18% |
Clinical OS | 237 |
Clinical Result source | ClinicalTrials.gov NCT01657682 |
Clinical Data Tier / Score | A · 28 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교